Grifols SA (GRF) - Financial and Strategic SWOT Analysis Review

Grifols SA (GRF) - Financial and Strategic SWOT Analysis Review


- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Grifols SA (Grifols) is a pharmaceutical and chemical manufacturing company engaged on enhancing the health and well-being of patients worldwide. It is focused on research, development, manufacturing and marketing of plasma-derived therapies, hospital pharmacy products and diagnostic technology for clinical use. The company produces plasma derived protein therapies for patients suffering with rare, chronic and life-threatening infections. Grifols offers biological materials for clinical trials, biotechnology research, manufacturing pharmaceutical and diagnostic products. Grifols provides transfusion medicine, hemostasis and immunoassay solutions for blood banks, clinical laboratories and transfusion centers. The company offers its products to hospitals, pharmacies and healthcare professionals. It offers products in the US, Canada, Europe, and Rest of the world. Grifols is headquartered in Barcelona, Spain.

Grifols SA Key Recent Developments

Dec 19,2023: Victor Grifols Roura Announces Retirement from Grifols Board of Directors; Albert Grifols ComaCros assumes the vacated seat
Dec 04,2023: Grifols Accelerates EBITDA Margin Expansion to 25.1% And Further Improves Its Operating Performance
Nov 16,2023: Grifols Launches New Solution to Facilitate Pre-transfusion Compatibility Testing in Multiple Myeloma Patients
Nov 13,2023: Grifols Receives FDA Approval for Expanded Immunoglobulin Purification and Filling Capacity at Its North Carolina Site

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note:Some sections may be missing if data is unavailable for the company


List of Tables
List of Figures
Section 1 - About the Company
Grifols SA - Key Facts
Grifols SA - Key Employees
Grifols SA - Key Employee Biographies
Grifols SA - Major Products and Services
Grifols SA - History
Grifols SA - Company Statement
Grifols SA - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Grifols SA - Business Description
Business Segment: Bio Supplies
Overview
Performance
Business Segment: Biopharma
Overview
Performance
Business Segment: Diagnostic
Overview
Performance
Business Segment: Others
Overview
Performance
Geographical Segment: European Union
Target Markets
Performance
Geographical Segment: Rest of the World
Performance
Geographical Segment: Spain
Performance
Geographical Segment: USA and Canada
Performance
R&D Overview
Grifols SA - Corporate Strategy
Grifols SA - SWOT Analysis
SWOT Analysis - Overview
Grifols SA - Strengths
Grifols SA - Weaknesses
Grifols SA - Opportunities
Grifols SA - Threats
Grifols SA - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Grifols SA, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
Grifols SA, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
Grifols SA, Recent Deals Summary
Section 5 – Company’s Recent Developments
Dec 19, 2023: Victor Grifols Roura Announces Retirement from Grifols Board of Directors; Albert Grifols ComaCros assumes the vacated seat
Dec 04, 2023: Grifols Accelerates EBITDA Margin Expansion to 25.1% And Further Improves Its Operating Performance
Nov 16, 2023: Grifols Launches New Solution to Facilitate Pre-transfusion Compatibility Testing in Multiple Myeloma Patients
Nov 13, 2023: Grifols Receives FDA Approval for Expanded Immunoglobulin Purification and Filling Capacity at Its North Carolina Site
Oct 19, 2023: GigaGen Granted Expansion of Contract with US Department of Defense to Develop Synthetic Human Antibody Treatments for Botulinum Neurotoxins
Sep 04, 2023: Grifols names Dr. Jorg Schüttrumpf Chief Scientific Innovation Officer
Aug 01, 2023: Grifols Accelerates Healthcare Innovation With Google Cloud’s AI and Analytics
Jul 31, 2023: Grifols Egypt Donation Centers Receive First International Plasma Industry Quality Certification Outside North America and Europe
Jul 27, 2023: Grifols Delivers 15% Revenue Growth, Accelerates Margin Expansion in Q2 and Raises Guidance for FY23
Jun 16, 2023: Grifols Highlights the Acceleration of Its Operating Performance and Reiterates Its Strong Commitment to Debt Reduction
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
Grifols SA, Key Facts
Grifols SA, Key Employees
Grifols SA, Key Employee Biographies
Grifols SA, Major Products and Services
Grifols SA, History
Grifols SA, Other Locations
Grifols SA, Subsidiaries
Grifols SA, Key Competitors
Grifols SA, Ratios based on current share price
Grifols SA, Annual Ratios
Grifols SA, Annual Ratios (Cont...1)
Grifols SA, Annual Ratios (Cont...2)
Grifols SA, Interim Ratios
Grifols SA, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
Grifols SA, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
Grifols SA, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Grifols SA, Performance Chart (2018 - 2022)
Grifols SA, Ratio Charts
Grifols SA, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
Grifols SA, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings